Patents by Inventor Olukayode Sosina

Olukayode Sosina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitors
    Patent number: 11957704
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: August 31, 2022
    Date of Patent: April 16, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
    Patent number: 11891607
    Abstract: The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.
    Type: Grant
    Filed: July 29, 2022
    Date of Patent: February 6, 2024
    Assignees: Regeneron Pharmaceuticals, Inc., The Royal Institution For the Advancement of Learning/McGill University
    Inventors: Jonas Bovijn, Olukayode Sosina, Sirui Zhou, Luca Andrea Lotta, Aris Baras, John Brent Richards
  • Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors
    Patent number: 11773393
    Abstract: The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing liver disease.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: October 3, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Niek Verweij, Luca Andrea Lotta, Aris Baras, Mary Haas, Jonas Nielsen, Olukayode Sosina, Adam Locke
  • Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitors
    Patent number: 11759476
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: September 19, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors
    Publication number: 20230172963
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: August 31, 2022
    Publication date: June 8, 2023
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment of Decreased Bone Mineral Density With Wnt Family Member 5B (WNT5B) Inhibitors
    Publication number: 20230083558
    Abstract: The present disclosure provides methods of treating subjects having decreased bone mineral density or at risk of developing decreased bone mineral density, methods of identifying subjects having an increased risk of developing decreased bone mineral density, methods of detecting Wnt Family Member 5B (WNT5B) variant nucleic acid molecules and variant polypeptides, and WNT5B variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: June 30, 2022
    Publication date: March 16, 2023
    Inventors: Jonas Bovijn, Olukayode Sosina, Luca Andrea Lotta, Aris Baras
  • Methods Of Treating Decreased Bone Mineral Density With Kringle Containing Transmembrane Protein 1 (KREMEN1) Inhibitors
    Publication number: 20230021584
    Abstract: The present disclosure provides methods of treating a subject having decreased bone mineral density or at risk of developing decreased bone mineral density, and methods of identifying subjects having an increased risk of developing decreased bone mineral density.
    Type: Application
    Filed: June 30, 2022
    Publication date: January 26, 2023
    Inventors: Jonas Bovijn, Olukayode Sosina, Luca Andrea Lotta, Aris Baras
  • Treatment Of Obesity With G-Protein Coupled Receptor 75 (GPR75) Inhibitors
    Publication number: 20220411870
    Abstract: The present disclosure provides methods of treating subjects having obesity, methods of identifying subjects having an increased risk of developing obesity, methods of detecting human G-protein coupled receptor 75 variant nucleic acid molecules and variant polypeptides, and GPR75 variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: May 19, 2022
    Publication date: December 29, 2022
    Inventors: Luca Andrea Lotta, Manuel Allen Revez Ferreira, Aris Baras, Parsa Akbari, Olukayode Sosina
  • Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors
    Publication number: 20220364099
    Abstract: The present disclosure provides methods of treating a subject having a liver disease or type 2 diabetes, and methods of identifying subjects having an increased risk of developing a liver disease or type 2 diabetes.
    Type: Application
    Filed: May 10, 2022
    Publication date: November 17, 2022
    Inventors: Niek Verweij, Olukayode Sosina, Parsa Akbari, Adam Locke, Aris Baras, Luca Andrea Lotta
  • Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors
    Publication number: 20220313726
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: April 1, 2022
    Publication date: October 6, 2022
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) Inhibitors
    Publication number: 20220282253
    Abstract: The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing liver disease.
    Type: Application
    Filed: March 31, 2022
    Publication date: September 8, 2022
    Inventors: Niek Verweij, Luca Andrea Lotta, Aris Baras, Mary Haas, Jonas Nielsen, Olukayode Sosina, Adam Locke
  • Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) Inhibitors
    Publication number: 20220220474
    Abstract: The present disclosure provides methods of treating subjects having a liver disease, and methods of identifying subjects having an increased risk of developing liver disease.
    Type: Application
    Filed: December 22, 2021
    Publication date: July 14, 2022
    Inventors: Niek Verweij, Luca Andrea Lotta, Aris Baras, Mary Haas, Jonas Nielsen, Olukayode Sosina, Adam Locke
  • Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors
    Publication number: 20220184114
    Abstract: The present disclosure provides methods of treating a subject having metabolic disorders and/or cardiovascular diseases, methods of identifying subjects having an increased risk of developing a metabolic disorder and/or a cardiovascular disease, and methods of detecting human Inhibin Subunit Beta E variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: December 13, 2021
    Publication date: June 16, 2022
    Inventors: Luca Andrea Lotta, Parsa Akbari, Olukayode Sosina, Manuel Allen Revez Ferreira, Aris Baras
  • Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitors
    Patent number: 11359246
    Abstract: The present disclosure provides methods of treating subjects having obesity, methods of identifying subjects having an increased risk of developing obesity, methods of detecting human G-protein coupled receptor 75 variant nucleic acid molecules and variant polypeptides, and GPR75 variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: June 14, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Luca Andrea Lotta, Manuel Allen Revez Ferreira, Aris Baras, Parsa Akbari, Olukayode Sosina
  • Treatment Of Obesity With G-Protein Coupled Receptor 75 (GPR75) Inhibitors
    Publication number: 20220042101
    Abstract: The present disclosure provides methods of treating subjects having obesity, methods of identifying subjects having an increased risk of developing obesity, methods of detecting human G-protein coupled receptor 75 variant nucleic acid molecules and variant polypeptides, and GPR75 variant nucleic acid molecules and variant polypeptides.
    Type: Application
    Filed: June 21, 2021
    Publication date: February 10, 2022
    Inventors: Luca Andrea Lotta, Manuel Allen Revez Ferreira, Aris Baras, Parsa Akbari, Olukayode Sosina